Recombinant Vaccines Market
Report ID: SQMIG35A2787
Report ID: SQMIG35A2787
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35A2787 |
Region:
Global |
Published Date: February, 2025
Pages:
219
|Tables:
59
|Figures:
64
Recombinant Vaccines Market size was valued at USD 11.2 Billion in 2024 and is poised to grow from USD 12.47 Billion in 2025 to USD 29.58 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026–2033).
Early vaccines relied heavily on exposure strategies, often involving the attenuation or inactivation of pathogens. But the advent of genetic engineering, genomics and recombinant DNA technologies has revolutionized vaccine development.
Recently, these new approaches have paved the way for newly developed vaccines in the market. Unlike traditional methods, these vaccines are developed under laboratory conditions using genetic screening techniques to eliminate the risk associated with infectious diseases. This not only ensures the effectiveness of the vaccines but also prioritizes safety in the vaccination process. The intersection of genetic engineering and vaccine development represents a significant leap forward, allowing for a more precise and targeted approach to immunization.
Market snapshot - 2026-2033
Global Market Size
USD 10.05 billion
Largest Segment
Adults
Fastest Growth
Adults
Growth Rate
11.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Human Papillomavirus (HPV) segment is poised to exhibit a substantial growth share throughout the forecast period. This distinctive name accounts for the increasing prevalence of human papillomavirus-associated infections in the general population. Continuous increases in health spending, and concerted efforts and initiatives from global authorities such as the United Nations International Children's Emergency Fund (UNICEF), the World Health Organization (WHO), and Pan American Public Health Organization (PAHO) have been instrumental in increasing the supply of vaccines targeting HPV.
The meningococcal segment plays an important role in the recombinant vaccines market, contributing significantly to the prevention of meningococcal infections. Meningococcal diseases caused by Neisseria meningitidis virus are a major public health problem due to potential early onset and severe consequences, including meningitis and septicemia. Recombinant vaccines targeting meningococcal species leading to technological advances in combating these diseases. They also provide an effective tool. Using recombinant DNA technology, these compounds can stimulate robust immune responses without the use of live bacteria, increasing safety and efficacy.
The adult segment is expected to account for significant growth throughout the forecast period, driven by several factors. The high rate of older patients with infectious diseases is an important indicator of this trend. Rising demand for recombinant vaccines, coupled with increased manufacturing capacity to meet unmet needs, further supports the dominance of the adult segment. Furthermore, vaccines and re-efficacy of various disease control mixes plays an important role in enhancing the growth of this segment.
The pediatric segment plays an important role in the recombinant vaccines market, being a keystone in the prevention of various infectious diseases affecting children. Recombinant vaccines designed for child use use advanced biotechnology techniques for vaccination safe and effective solutions. These vaccines aim to protect children against certain diseases such as measles, mumps, rubella, and influenza Using recombinant DNA technology, these vaccines are precise with a targeted approach for immune stimulation without the use of live bacteria.
To get detailed segments analysis, Request a Free Sample Report
North America emerged as the dominant region in the recombinant vaccines market, a trend expected to continue throughout the forecast period. The region dominates due to a combination of factors, such as high prevalence of chronic diseases, a significantly higher number of players, and higher vaccination rates offered. stimulating a dynamic approach to vaccination strategies.
Asia-Pacific is poised to record the highest annual growth rate (CAGR) during the analyzed period, driven by several primary factors. The presence of densely populated countries such as India and China contributes significantly to diseases causing widespread infection in the region. Furthermore, rising product launches and other factors being adopted by market players influence the market growth in Asia-Pacific.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increase in Sales of Genetically Modified Vaccines
High Cost Associated with Per Dose Vaccine
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment of the global Recombinant Vaccines market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. Major pharmaceutical companies including GSK and Merck invest heavily in research and development (R&D) to advance genetically modified vaccines for example GSK has an extensive pipeline that includes hepatitis B, meningococcal B, papillomavirus, respiratory syncytial virus infection, rotavirus etc. This leads to innovations targeted at various infection candidates. A new effective commitment to address infectious diseases lies in a focused approach to vaccine introduction. The concerted efforts of key market players including GSK and Merck are crucial in boosting the growth of the global market, which is expected to register a compound annual growth rate (CAGR) during the analyzed period.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 11.2 Billion |
| Market size value in 2033 | USD 29.58 Billion |
| Growth Rate | 11.4% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Recombinant Vaccines Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Recombinant Vaccines Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Recombinant Vaccines Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Recombinant Vaccines Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
